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TUBB4A de novo mutations cause
isolated hypomyelination
ABSTRACT
Objective: We present a series of unrelated patients with isolated hypomyelination, with or with-
out mild cerebellar atrophy, and de novo TUBB4A mutations.
Methods: Patients in 2 large institutional review board–approved leukodystrophy bioregistries at
Children’s National Medical Center andMontreal Children’s Hospital with similar MRI features had
whole-exome sequencing performed. MRIs and clinical information were reviewed.
Results: Five patients who presented with hypomyelination without the classic basal ganglia
abnormalities were found to have novel TUBB4A mutations through whole-exome sequencing.
Clinical and imaging characteristics were reviewed suggesting a spectrum of clinical manifestations.
Conclusion: Hypomyelinating leukodystrophies remain a diagnostic challenge with a large per-
centage of unresolved cases. This finding expands the phenotype of TUBB4A-related hypomyeli-
nating conditions beyond hypomyelination with atrophy of the basal ganglia and cerebellum.
TUBB4A mutation screening should be considered in cases of isolated hypomyelination or hypo-
myelination with nonspecific cerebellar atrophy. Neurology® 2014;83:898–902
GLOSSARY
DYT4 5 dystonia type 4; H-ABC 5 hypomyelination with atrophy of the basal ganglia and cerebellum; TUBB4A 5 tubulin,
beta 4A class IVa.
Hypomyelinating leukodystrophies remain a diagnostic challenge with a large percentage of
unresolved cases.1 Herein, we report on a series of unrelated patients with isolated hypomye-
lination, with or without mild cerebellar atrophy, and de novo TUBB4A mutations.
Mutations in TUBB4A (MIM 602662) are known to cause either dystonia type 4 (DYT4
[MIM 128101]) or hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC
[MIM 612438]).2,3 In DYT4, an autosomal dominant mutation (c.4C.G [p.Arg2Gly]) in
TUBB4A (NM_006087.2) was identified in patients presenting with a “whispering” dysphonia,
generalized dystonia, and gait ataxia, but normal MRI features.2 In H-ABC, a cohort of 11
individuals were found to have a common de novo mutation at c.745G.A (p.Asp249Asn) in
TUBB4A.3
H-ABC is a rare leukodystrophy diagnosed on the basis of distinctive MRI findings including
hypomyelination, cerebellar atrophy, and absence or disappearance of the putamen at an early
age.4,5 Individuals with H-ABC present with developmental delay, extrapyramidal movement
disorders (dystonia, choreoathetosis, rigidity, opisthotonos, and oculogyric crises), ataxia, and
spastic tetraplegia with variable onset and in some cases seizures.4,5
Herein, we describe novel de novo mutations in TUBB4A in 5 patients belonging to 4
families with hypomyelinating leukodystrophy, and who lack the full complement of features
associated with H-ABC. This finding expands the phenotype of TUBB4A-related hypomyeli-
nating conditions beyond H-ABC and suggests that TUBB4A should be considered in cases of
isolated hypomyelination.
*These authors contributed equally this work.
‡Denotes Senior Author.
Authors’ affiliations are listed at the end of the article.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
898 © 2014 American Academy of Neurology
METHODS Standard protocol approvals, registrations,
and patient consents. This study was performed under the
approval of institutional review boards at Children’s National Med-
ical Center or Montreal Children’s Hospital. Blood was collected
and DNA extracted with informed consent from all subjects and
their parents. The DNA was analyzed using exome sequencing as
previously described.3 Of note, these cases were tested as part of a
larger cohort analysis in patients with unsolved leukodystrophies,
and not due to any prior suspicion of TUBB4A-related disorders.
Analysis was performed on trio or great family groups in all cases.
Sanger sequencing was used to validate and perform segregation
analysis of all candidate mutations.
RESULTS In all 5 cases, we identified novel de novo
mutations in TUBB4A (table). All of the patients have
similar MRI features including hypomyelination but
did not present with severe basal ganglia involvement
characteristic of H-ABC (figure 1). These 5 patients
presented with a diverse clinical spectrum (see supple-
mental data on the Neurology® Web site at Neurology.
org) as well as a broad range of neuroradiologic
features, some of which are also seen in H-ABC
(table). Patient 4 presented with cerebellar atrophy
from a young age while patients 3 and 5 have
isolated hypomyelination. Patients 1 and 2 have
global atrophy, as often seen in patients with long-
standing hypomyelinating disorders.
DISCUSSION These patients were ascertained as
cases of unsolved hypomyelination without any
radiologic or clinical features permitting a more
specific diagnosis. These cases unexpectedly all had
de novo TUBB4A mutations distinct from the
original H-ABC–related mutation, at c.745G.A
(p.Asp249Asn). The c.845G.C variant shared by
patients 1 and 2 was not identified in either parent
when tested by exome or Sanger sequencing. We
hypothesize that there is likely low-level parental
mosaicism, as was identified in the sibling group in
the original description of TUBB4A mutations in
H-ABC.3 Unfortunately, because of the older age of
these patients (in their fifth decade), it was no longer
possible to obtain new parental samples to test this
hypothesis. In the other families, parental testing by
exome and standard sequencing did not identify these
variants in the parents.
Missense mutations in genes that code for a- and
b-tubulin proteins, essential for assembly of neuronal
microtubules, have been shown to cause a group of
neurologic disorders characterized by abnormal neu-
ronal migration, differentiation, axon guidance, and
maintenance.6 Mutations in TUBA1A (MIM
602529), TUBA8 (MIM 605742), TUBB2B (MIM
612850), TUBB3 (MIM 602661), and TUBB4A
have all contributed to this spectrum of disorders.
The clinical variability between DYT4 and H-ABC
(late-childhood or juvenile-onset dystonia vs severe
pediatric-onset dystonia and quadriparesis) suggests
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that the TUBB4A gene is associated with a spectrum
of clinical manifestations. Other genes associated
with hypomyelinating leukodystrophies are also
known to cause a disease spectrum, varying from
severe spastic quadriparesis with limited functional
ability to mild spastic paraplegia. For example,
PLP1 (MIM 300401) mutations cause Pelizaeus-
Merzbacher disease (MIM 312080) as well as spas-
tic paraplegia 2 (MIM 312920).7 Similar examples
exist for Pol III–related leukodystrophies (4H or
Hypomyelination with Hypogonadotropic Hypogo-
nadism and Hypodontia)8 and Pelizaeus-Merzbacher–
like disease caused by GJC2 mutations.9 It is therefore
reasonable to predict that TUBB4A mutations could
present similar variability in the context of hypomyeli-
nating leukodystrophy.
TUBB4A is a neuronally expressed member of the
b-tubulin protein family, and forms heterodimers with
a-tubulins. The ab heterodimers polymerize to form
microtubules, an essential component of the cytoskel-
eton. The previously described residues associated with
H-ABC (p.Asp249) and DYT4 (p.Arg2) both sit near
the intradimer interface between a- and b-tubulin
(figure 2). The c.763G.A de novo mutation found
in patient 4 results in the amino acid change p.Val255Ile;
this residue is located in the same a-helix as p.Asp249
(figure 2). Val255 is exposed to the intradimer interface.
Mutations at this position may affect heterodimer for-
mation or stability.
The c.845G.C variant shared by patients 1 and 2
results in the amino acid change p.Arg282Pro and is
located in the structure known as theM-loop (figure 2).
The M-loop extends from the side of tubulin mono-
mers and is largely responsible for stabilizing the lateral
contact between adjacent tubulin protofilaments.10 The
conformational change resulting from the introduction
of a proline into the middle of the M-loop is likely to
destabilize this interaction. The p.Q292K change
caused by the c.874C.A mutation in patient 3 is
located in the a-helix H9; this helix is also believed
to participate in the lateral contacts between adjacent
protofilaments.10 Finally, the c.1172G.A mutation in
patient 5 results in the amino acid change p.Arg391His.
This residue is located near the interdimer interface
Figure 1 Brain sagittal T1, axial T2, and axial T1 MRIs of participants
(A) Patient 1 at age 45 years. Note the generalized atrophy with preserved putamen (white arrow) and hypomyelination (T1- and T2-hyperintensity of the
cerebral white matter). (B) Patient 2 at age 42 years. Note the generalized atrophy with preserved putamen (white arrow) and hypomyelination (T1- and
T2-hyperintensity of the cerebral white matter). (C) Patient 3 at age 4 years. Note the hypomyelination (T1- and T2-hyperintensity of the white matter) with
preserved putamen (white arrow) and cerebellum. Only postcontrast T1-weighted image available. (D) Patient 4 at age 5 years. Note the preserved putamen
(white arrow) and hypomyelination (T1- and T2-hyperintensity of the white matter). Mild atrophy of the cerebellar vermis is seen (thick white arrow). Only
postcontrast T1-weighted image available. (E) Patient 5 at age 10 years notable for preserved putamen (white arrow) and mild hypomyelination (T1- and
T2-hyperintensity of the white matter). No axial T1-weighted images were available. A repeat study at 14 years showed no putamen atrophy. (F) Typical
H-ABC MRI of the brain at age 9 years with absences of putamen (white arrow) and hypomyelination (T1- and T2-hyperintensity of the white matter), as well
as cerebellar atrophy (thick white arrow). H-ABC 5 hypomyelination with atrophy of the basal ganglia and cerebellum.
900 Neurology 83 September 2, 2014
(figure 2), thus this mutation may affect the polym-
erization of heterodimers.
Overall, these mutations are hypothesized to have a
similar impact of tubulin polymerization and stability
as the previously described c.745G.A (p.Asp249Asn)
in TUBB4A identified in H-ABC. Although all pa-
tients have hypomyelination with or without cerebellar
atrophy, as seen in H-ABC, no patients in the cohort
have putamen atrophy, despite nearly 5 decades of
disease progression in patients 1 and 2. This suggests
that mutations in TUBB4A other than p.Asp249Asn
can result in a phenotype of isolated hypomyelination,
albeit with or without nonspecific cerebellar atrophy.
Further monitoring is required to determine the
full clinical spectrum of these mutations because it
is difficult to ascertain what may develop over time,
in particular for the younger 2 patients. However,
even if it is possible that these patients could develop
additional imaging features consistent with H-ABC
over time, it remains important, based on these find-
ings, to consider TUBB4A mutation screening in
cases of isolated hypomyelination or hypomyelination
with nonspecific cerebellar atrophy.
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New Neurology Compensation and Productivity Report:
How Do You Compare?
The AAN’s 2014 Neurology Compensation and Productivity Report is now available. Based on data
from hundreds of neurologists and neurology practice managers, this is the most recent and reliable
information on the neurology profession.
The Neurology Compensation and Productivity Report is a powerful, versatile tool that can help you:
• Compare your salary, productivity, and practice characteristics to your peers—and use this
information in contract negotiations
• Evaluate physician performance compared to your peers
• Discover fair-market value based on customizable filters such as your subspecialty, region,
and practice type
• Analyze whether it makes sense to expand your practice
• Identify variances in key metrics for use in practice improvements
Learn more at AAN.com/view/2014NeuroReport.
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